Medicare Advantage and Cancer: What Breast Cancer Patients Must Know

For most healthy Medicare beneficiaries, a Medicare Advantage plan can look like a smart deal — lower premiums, dental and vision add-ons, and a single card for most needs. But for people facing a breast cancer diagnosis, or those with a family history who want to protect themselves against that possibility, Medicare Advantage plans carry risks that deserve a hard, honest look. The financial exposure, the treatment access hurdles, and the difficulty of escaping a plan once you're seriously ill can combine into a situation that is genuinely dangerous for your health and your finances.

The core issue with Medicare Advantage and cancer care comes down to two words: prior authorization. Unlike Original Medicare, which generally covers medically necessary treatments without requiring advance approval from an insurer, Medicare Advantage plans are run by private insurance companies that are permitted to require prior authorization before approving chemotherapy, radiation, surgery, imaging, and specialist visits. A 2022 report from the HHS Office of Inspector General found that Medicare Advantage plans denied 13% of prior authorization requests that would have met Original Medicare's coverage standards. For a breast cancer patient waiting on approval for a PET scan to determine whether cancer has spread, or waiting for authorization to begin a specific chemotherapy regimen, those delays are not administrative inconveniences — they can affect treatment outcomes.

Network restrictions compound the problem. Medicare Advantage plans use HMO and PPO structures that limit which doctors and hospitals you can use at the in-network cost level. Major cancer centers — places like MD Anderson, Memorial Sloan Kettering, Mayo Clinic, and regional NCI-designated cancer centers — are frequently out-of-network for many Medicare Advantage plans. In 2024, a KFF analysis found that only about half of Medicare Advantage enrollees had access to a National Cancer Institute-designated cancer center within their plan's network. If your oncologist or the hospital best equipped to treat your specific cancer type is out-of-network, you either pay dramatically higher out-of-pocket costs or you switch providers mid-treatment, which most oncologists will tell you is something to avoid whenever possible.

The out-of-pocket exposure in Medicare Advantage is real and significant. In 2025, the maximum out-of-pocket limit for Medicare Advantage plans is $9,350 for in-network services and can be higher when out-of-network costs are included — some plans set combined limits above $14,000. Breast cancer treatment — surgery, reconstruction, chemotherapy, radiation, hormone therapy, targeted therapy drugs like trastuzumab (Herceptin) — can easily push a patient to that ceiling within the first few months of diagnosis. Once you hit the out-of-pocket maximum, the plan covers 100% for the rest of the year, but that reset happens on January 1. A patient diagnosed in October could hit their maximum, reset on January 1, and face the full cost-sharing structure again just as treatment continues. This annual reset cycle is one of the most financially punishing aspects of Medicare Advantage for people with serious, ongoing conditions.

Hospital indemnity insurance is one tool that can help bridge the gap for Medicare Advantage enrollees who find themselves facing cancer-related hospitalizations. A hospital indemnity policy pays a fixed cash benefit — typically ranging from $100 to $500 or more per day — directly to you when you're admitted to a hospital, regardless of what your Medicare Advantage plan pays or denies. For a breast cancer patient who needs a mastectomy, reconstruction, or a hospital stay related to chemotherapy complications, a hospital indemnity benefit can help cover the cost-sharing, transportation, lodging for family, lost income, or any other expense that insurance doesn't touch. These policies are not a substitute for comprehensive coverage, but for someone locked into a Medicare Advantage plan who cannot easily switch, a hospital indemnity plan can provide meaningful financial cushion. Premiums vary widely by age and benefit level, but many plans are available for $50 to $150 per month for a 65-70 year old.

The most important — and most overlooked — issue for cancer patients in Medicare Advantage is what happens when they try to leave. During the Annual Enrollment Period (October 15 through December 7 each year), any Medicare beneficiary can switch from Medicare Advantage back to Original Medicare. But Original Medicare alone leaves you exposed to 20% coinsurance with no cap, which for cancer treatment can mean tens of thousands of dollars in exposure. To protect yourself, you'd want to add a Medigap supplemental policy. Here's the problem: in most states, Medigap insurers can use medical underwriting outside of guaranteed issue windows, meaning they can deny you coverage or charge you higher premiums based on your health history. A breast cancer diagnosis is exactly the kind of pre-existing condition that can make you uninsurable for Medigap in states that don't have additional protections.

Guaranteed issue rights for Medigap do exist in specific situations — for example, if you're in your first 12 months of a Medicare Advantage plan and want to switch back, or if your plan leaves your area or loses its Medicare contract. But if you've been in a Medicare Advantage plan for several years and then receive a cancer diagnosis, you may find yourself unable to get a Medigap policy without medical underwriting approval. A handful of states offer broader protections. New York and Connecticut have guaranteed issue for Medigap year-round, regardless of health status. California, Oregon, Idaho, Illinois, Kentucky, Louisiana, Maine, Maryland, Missouri, Nevada, New Jersey, Oklahoma, and several others have birthday rules that give you a 30-day window each year around your birthday to switch Medigap plans without underwriting — though this typically applies to switching between Medigap plans, not to someone enrolling in Medigap for the first time from Medicare Advantage. If you live in one of these states, understanding exactly what your state's rules allow is critical — contact your State Health Insurance Assistance Program (SHIP) counselor for free, personalized guidance, or reach out to your state insurance commissioner's office.

For people who are currently healthy and enrolled in Medicare Advantage, the time to think about this is before a diagnosis, not after. If you have a strong family history of breast cancer, or if you've had prior breast cancer and are in remission, the question of whether Medicare Advantage is the right long-term structure for your coverage deserves serious attention. Original Medicare combined with a Medigap Plan G — the most comprehensive option available to new Medicare enrollees since 2020 — typically runs $100 to $200 per month in premiums depending on your age, location, and insurer, but it provides access to any doctor or hospital that accepts Medicare nationwide, no prior authorization for covered services, and no network restrictions. For someone at elevated cancer risk, that freedom of access may be worth more than the premium savings a Medicare Advantage plan offers.

If you're already in a Medicare Advantage plan and have been diagnosed with breast cancer, you have options worth exploring immediately. The Medicare Advantage Open Enrollment Period runs January 1 through March 31 each year, during which you can switch to a different Medicare Advantage plan or return to Original Medicare — though the Medigap underwriting issue still applies in most states. You can also file appeals when prior authorization is denied; Medicare Advantage plans are required to have an appeals process, and a 2023 KFF study found that beneficiaries who appeal denials win a significant portion of the time. Your oncologist's office can often assist with the appeals process, and a patient advocate or SHIP counselor can help you navigate it. The bottom line is that Medicare Advantage is not inherently bad for everyone, but for people with breast cancer or significant cancer risk, the access restrictions, prior authorization hurdles, and Medigap lock-in risks create a combination of vulnerabilities that every beneficiary deserves to understand clearly before making an enrollment decision.